PAGITANE
LOE ApproachingNDAORALTABLET
Approved
Jul 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PAGITANE is an oral small-molecule tablet approved by Eli Lilly in 1953 for an undisclosed indication. The specific mechanism of action and therapeutic class remain proprietary or legacy information not currently documented in public records. This is a legacy NDA product with significant historical tenure in the market.
LOE Approaching
With LOE approaching and zero linked job openings, this product is in managed decline; minimal commercial infrastructure expansion anticipated.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PAGITANE has zero linked job openings, indicating minimal hiring or team expansion at present. Working on this product offers limited growth trajectory and is best positioned for experienced professionals managing legacy asset transitions or cost-optimization initiatives.
Brand ManagerCommercial Operations Manager
Worked on PAGITANE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.